Improving Physiological, Physical, and Psychological Health Outcomes: A Narrative Review in US Veterans with COPD

Patricia M Bamonti, Stephanie A Robinson, Emily S Wan, Marilyn L Moy

Abstract: The Veterans Health Administration (VHA) is the largest integrated healthcare system in the United States (US) providing healthcare to an increasing number of middle-aged and older adults who remain at greater risk for chronic obstructive pulmonary disease (COPD) compared to their civilian counterparts. The VHA has obligated research funds, drafted clinical guidelines, and built programmatic infrastructure to support the diagnosis, treatment, and care management of Veterans with COPD. Despite these efforts, COPD remains a leading cause of morbidity and mortality in Veterans. This paper provides a narrative review of research conducted with US Veteran samples targeting improvement in COPD outcomes. We review key physiological, physical, and psychological health outcomes and intervention research that included US Veteran samples. We conclude with a discussion of directions for future research to continue advancing the treatment of COPD in Veterans and inform advancements in COPD research within and outside the VHA.

Keywords: chronic obstructive pulmonary disease, U.S. Veterans, interventions

Introduction

Approximately 7–8% of adults in the United States (US) currently identify as Veterans of the Armed Forces; of these, approximately 42–49% are recipients of Veteran Affairs (VA) benefits, which include services such as healthcare, disability compensation or pension, loan and insurance programs, and burial services. In general, Veterans who complete a minimum 24 months of service with an honorable discharge are eligible for healthcare through the Veterans Health Administration (VHA), one of the largest nationally integrated systems. Although VA benefits are available to most Veterans, due to priority assignments for enrollment (based on service connection, disability, and income) and copays, the approximately 9 million Veterans who currently utilize VA healthcare and participate in VA-sponsored research represent a unique subset of the Veteran population.

Recipients of VA healthcare are typically older than the general population (median age 64 versus 38 years, respectively) and are predominantly (91%) male, although enrollment of female Veterans is rising. The proportion of Veterans who utilize VA with an annual household income less than $35,000 is higher than that of the general US population (43% versus 26%) as is the prevalence of ever-smoking (60% versus 35–40%). Economic disadvantage and increased rates of smoking, coupled with service-related and occupational exposures, have likely contributed to the high prevalence and rising incidence of chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), among Veterans.

COPD is not objectively different in terms of disease manifestation in Veterans compared to civilians. However, the prevalence of COPD among Veterans, which is currently estimated to be between 8% and 19%, is higher than among the general population (6%). Importantly, COPD is likely underdiagnosed among Veterans, with only a minority of
individuals with objective airflow limitation on lung function testing reporting a clinical diagnosis of COPD. Veterans with COPD have increased all-cause and respiratory-related health-care utilization as well as higher rates of comorbid conditions relative to Veterans without COPD. Moreover, the prevalence of mental health conditions, particularly alcohol and substance abuse, is higher in Veterans compared to civilians. Comorbid mental health conditions commonly serve as a barrier to utilization and/or responsiveness to evidence-based care, such as self-management interventions. Given the prevalence and significant burden of COPD within the VHA, substantial resources have been applied towards both clinical and research initiatives to improve outcomes for Veterans with COPD.

The VHA provides evidence-based treatment to Veterans with COPD in order to optimize physiological, physical, and psychological health. These treatments and interventions are comprehensively described in the Global Initiative for Obstructive Lung Disease (GOLD) guidelines. Notably, Veterans with COPD and VHA researchers have contributed to early research examining such treatments and interventions to improve COPD outcomes. The objective of this paper is to provide a narrative review of interventions for key physiological, physical, and psychological health outcomes in US Veterans. Articles were identified if they were conducted with US Veterans and broadly addressed interventions for physiological, physical, or psychological outcomes.

**Physiological Outcomes and Interventions to Optimize Them in Veterans with COPD**

Due to the high burden of COPD within the VA, Veterans and VHA investigators have been involved in studies which have contributed to the collective knowledge on COPD physiology. Physiological and clinical outcomes which have been examined among Veterans with COPD have included lung function, hypoxemia, and systemic effects associated with disease, such as alterations in body composition and bone mineral density. These studies support current evidence-based guidelines which include both pharmacological and non-pharmacological management of both stable COPD and acute exacerbations of COPD. Key studies examining these physiological and clinical outcomes are summarized below.

Longitudinal studies based within the VHA, such as the Normative Aging Study (NAS), have resulted in an improved understanding of and delineation between healthy aging and disease processes such as COPD. Comprised of over 2000 participants who were first enrolled in 1963 who have triennial follow-up data, the NAS represents a rich source of multi-dimensional information contributing to studies which have identified environmental (eg, smoking, air pollution) as well as genetic, epigenetic, and genomic risk factors that affect lung function and COPD susceptibility.

**Oxygen Supplementation**

VHA research was a key stakeholder in establishing the detrimental effects of hypoxemia on not only end organ function but also reactive vasoconstriction in the pulmonary vasculature leading to pulmonary hypertension and cor pulmonale. Sentinel publications supported by the VHA include a brief report by Renzetti et al in 1968 which established the associations between COPD and mortality, spirometric lung function, and hypoxemia. Findings from this observational report gave rise to numerous subsequent studies, both within and outside of the VHA, which established the safety and benefit of supplemental oxygen on exercise tolerance and dyspnea, cardiovascular parameters, and survival among COPD patients with significant hypoxemia. As research practices evolved over the decades from single-site studies to multi-center collaborative initiatives, VA investigators continued to contribute to research on the management of hypoxemia in COPD patients. Multiple VA facilities served as research study sites for the Long-Term Oxygen Treatment Trial (LOTT) which examined oxygen supplementation for COPD patients with moderate resting or exercise-induced hypoxemia. While the benefits of oxygen supplementation in COPD patients with severe resting hypoxemia (defined as an oxygen saturation (SpO₂) <89% or an arterial oxygen tension, PaO₂ ≤55 mmHg, or PaO₂≤59 or SpO₂≤89% with signs of cor pulmonale) had been previously established, LOTT demonstrated that routine supplementation in moderate resting (SpO₂ 89–93%) or exercise-induced hypoxemia (SpO₂ 80–90%) was not associated with improved all-cause mortality or time to first hospitalization, leading to a significant revision of management guidelines issued by the VHA, professional societies, and the GOLD recommendations.
guidelines on the initiation of oxygen supplementation (as outlined above) as well as the titration of supplemental oxygen to a goal $\text{SpO}_2 > 90–92\%$ represent the integrated results of trials conducted both within and outside the VHA.

**Pharmacological Management**

Veterans and VHA investigators have contributed substantially to studies of medications, such as bronchodilators, that improve symptoms through improvements in lung function by increasing airway diameter and decreasing air trapping and hyperinflation. Early trials examined systemic bronchodilators, such as theophylline, metaproterenol, and metaproterenol, and were later supplanted by studies of inhaled beta-agonists and antimuscarinic agents, the two dominant classes of bronchodilators in use today. Use of long-acting inhaled beta-agonists and antimuscarinic agents is currently recommended as first-line, evidence-based maintenance therapies for COPD. Additional studies of pharmacological agents have included investigations of the effect of morphine on dyspnea, an important strategy for the palliative care of Veterans with advanced chronic lung disease associated with air hunger.

Significant morbidity is attributed to acute exacerbations of COPD and investigations into pharmacological strategies to treat and prevent these events have also involved Veteran populations. In a multi-center, randomized controlled trial (RCT) sponsored by the VA Cooperative Studies Program (CSP), systemic corticosteroids for Veterans hospitalized with acute exacerbations of COPD were found to reduce the incidence of a combined endpoint of all-cause mortality, mechanical ventilation, readmission for COPD, or escalation of therapy relative to placebo. Systemic corticosteroids are now considered the standard of care for management of acute exacerbations of COPD, although the optimal doses and duration of therapy remain active areas of investigation.

Significant resources have also been allocated to preventing acute exacerbations among COPD patients. Multiple VA medical centers served as research study sites for a RCT of chronic macrolide therapy using azithromycin to target chronic airways inflammation and prevent acute exacerbations of COPD. Findings from the study, which examined daily azithromycin taken for a year in addition to usual therapy, were notable for decreased COPD exacerbations and improved health-related quality of life (HRQoL), but also increased risk for hearing loss. Chronic suppressive macrolide therapy is now endorsed by the GOLD guidelines as an adjunctive maintenance medication for exacerbation-prone individuals.

The performance of roflumilast, another pharmacological agent for the prevention of exacerbations, was examined relative to chronic suppressive azithromycin use among Veterans. In this observational study, the unified medical records system within the VHA, known as the Corporate Data Warehouse, was examined along with Medicare usage data for 3875 Veterans. Results showed that roflumilast, an oral selective phosphodiesterase-4 inhibitor, was associated with increased all-cause mortality and COPD-related hospitalizations relative to chronic suppressive macrolide therapy. The findings from this study supported the need for head-to-head studies of chronic macrolide therapy relative to roflumilast which are currently being investigated through an ongoing RCT (clinicaltrials.gov NCT04069312).

**Systemic Effects of COPD**

Although airflow obstruction is the defining feature of COPD, there is increasing appreciation of the extra-pulmonary and systemic consequences of COPD. Due to the higher rates of and cumulative exposure to smoking, as well as intermittent use of systemic corticosteroids, COPD has been identified as an independent risk factor for osteoporosis among Veterans. The clinical consequences of the increased prevalence of osteoporosis were subsequently confirmed in a study of 87,360 Veterans aged >50 years with newly diagnosed COPD between 1999 and 2003, where high rates of hip and wrist fragility fractures were observed. Additional findings from this study included low rates of bone mineral density testing and anti-resorptive treatment (eg, bisphosphonates) and identified a crucial need for screening for bone health among Veterans with COPD.

In addition to bone health, there has been increasing attention given to the impact of differences in body mass and body composition among Veterans with COPD. Body-mass index (BMI), a widely used metric of the weight-to-height relationship, is an integral component of the BMI, obstruction, dyspnea, and exercise limitation (BODE) index, which correlates with mortality and exacerbation frequency in COPD and has been validated in Veterans. In addition to body mass, the role of fat-free mass, a proxy measure for muscle mass, and its relationship with functional outcomes and exercise tolerance in Veterans with COPD represent important future areas of research.
Care Coordination Interventions
Other work in Veterans to improve physical outcomes in COPD has focused less on the individual patient, and more on the quality and type of care the patient receives. Although the majority of COPD-related care is managed by primary care providers, Veteran access to specialty care and referrals patterns to pulmonologists for COPD are comparable to those in the general community. A significant proportion of the morbidity and direct costs associated with COPD within the VHA arise from hospitalizations due to acute exacerbations of COPD. In an effort to develop and introduce programs to reduce COPD hospitalizations, the VHA sponsored a multicenter RCT examining the efficacy of a multidisciplinary comprehensive care management plan comprised patient and primary care provider education, the development of an action plan for exacerbation management, and proactive case management relative to usual care. Unfortunately, the study was terminated prematurely in 2012 due to increased rates of COPD-related hospitalizations and excess all-cause mortality in the intervention (comprehensive care) arm. Notably, similar results for comprehensive care programs at non-VHA hospitals have subsequently been reported, supporting that additional research and alternative strategies for preventing COPD hospitalizations are needed.

While effective strategies to prevent COPD hospitalizations remain an active field of investigation, programs to reduce the length of stay and prevent re-admissions have also received priority within the VHA. VHA-wide initiatives to reduce hospital utilization through expanded outpatient care resulted in a 51% reduction in length of stay for COPD exacerbations over 1994–1998, notably without increased mortality or non-VA hospital use. Additionally, individual programs focused on coordinated transitional care, a nurse-driven, telephone-based program targeting high-risk patients with comorbid COPD and congestive heart failure prior to discharge to home at an urban VA medical center resulted in a 54% reduction in 30-day re-hospitalization risk and was shown to be cost-effective. Moreover, one study examined the association of using non-VA outpatient care (both VA and non-VA care [ie, dual-care], and non-VA care only) and VA-only care with 30-day re-admission among Veterans. Overall, compared to Veterans who received VA-only care, Veterans who received dual-care and non-VA care only were 20% more likely to be readmitted for a COPD-specific exacerbation. These initiatives likely explain the recent finding of lower rates for 30-day re-admissions following hospitalizations for COPD at VA relative to non-VA hospitals.

Physical Outcomes and Interventions to Improve Them in Veterans with COPD
An overarching goal in the treatment of Veterans with COPD is to maximize physical function. However, the clinical course of COPD can contribute to a vicious cycle of reduced function. Patients who experience dyspnea, a major symptom of COPD, tend to avoid physical activities that worsen dyspnea, causing further muscle deconditioning and reductions in exercise capacity. Pain is another common symptom of COPD, which can also contribute to lower physical function. Physical outcomes, such as dyspnea, exercise capacity, physical activity (PA), and pain, reflect potentially modifiable risk factors of all-cause and respiratory-related mortality. As such, there has been great interest within VHA to develop effective interventions to improve physical outcomes in Veterans with COPD. The following sections detail several of these interventions, and highlight the impact of these interventions on dyspnea, PA, exercise capacity, pain, and risk for acute COPD exacerbations.

Pulmonary Rehabilitation
Pulmonary rehabilitation (PR) is a well-established treatment of COPD, effectively improving exercise capacity, dyspnea, and HRQoL. PR is a comprehensive intervention that focuses on exercise training and self-management education. It typically occurs 2–3 times a week across 8–12 weeks. Access to traditional, in-person PR can be difficult. In the VA with regional medical centers, distance is a significant barrier. In the National Emphysema Treatment Trial, participants who lived greater than 36 miles from the treatment facility were 51% less likely to complete PR compared to those who lived less than 6 miles away. In one urban VA medical center, 25% of initially evaluated Veterans never started PR, 29% dropped-out, while only 46% completed a full course of 18 sessions. Some Veterans who would benefit from PR decline participation due to access-related barriers, such as time and distance to travel to the program. Earlier work within VA compared outcomes in Veterans who completed PR to Veterans who were referred to PR but declined.
Overall, Veterans with COPD who completed PR significantly improved exercise capacity, as measured with the 6-minute walk test (6MWT) by an average of 75 m and reported a decrease in dyspnea on the UCSD Shortness of Breath Questionnaire by 7.3 points.\textsuperscript{52} Additionally, COPD-related acute emergency visits and hospitalizations declined post-PR.\textsuperscript{52} More recently, predictors of Veterans’ PR engagement were examined through a retrospective study of Veterans who attended their initial PR intake session between 2010 and 2018.\textsuperscript{50} Participants who dropped out of PR (ie, dropped out before session 18) compared to completers (ie, Veterans who completed all 18 session) had worse dyspnea, as measured by the Chronic Respiratory Questionnaire-Self-Reported (CRQ-SR) at baseline, and were more likely to be current smokers and have a history of alcohol use disorder. No differences emerged between those who never started and those who dropped out.\textsuperscript{50} Thus, while PR is unequivocally effective for improving physical outcomes, it is important that future work continue to address ongoing access barriers to PR.

Physical Activity and Exercise Interventions

Patients with COPD tend to engage in significantly less daily PA compared to healthy-matched controls.\textsuperscript{53} Physical activity as an outcome is important in COPD, as it is directly associated with poor health outcomes such as increased risk of acute exacerbations and increased mortality, independent of lung function.\textsuperscript{54} Many factors can contribute to lower levels of PA, including physiologic, behavioral, and environmental factors.\textsuperscript{55} As such, there has been a substantial amount of work within VA to develop effective interventions that promote and sustain PA and exercise.

There have been several related RCTs examining the effectiveness of a web-mediated, pedometer-based PA intervention in Veterans with COPD (Taking Healthy Steps,\textsuperscript{56} Every Step Counts,\textsuperscript{57} and Walking and Education to Breathe\textsuperscript{58}). This web intervention provides Veterans with COPD personalized daily step count goals, iterative feedback, disease-specific education, motivational tips, and an online community forum. Taking Healthy Steps was a RCT conducted virtually in a national sample of Veterans with COPD identified by diagnosis code. Compared to those who were randomly assigned to use a pedometer alone, those who were assigned to the website walked on average 779 more steps per day at 4 months.\textsuperscript{56} Every Step Counts used a more well-characterized cohort (ie, COPD diagnosis validated via spirometry). Compared to the pedometer-only control group, Veterans assigned to the website significantly increased their daily step count by 804 steps at 3 months.\textsuperscript{57} Those assigned to the intervention also demonstrated a significant reduced risk of experiencing a COPD acute exacerbation across a 12-month follow-up.\textsuperscript{59} Walking and Education to Breathe, the most recent RCT, evaluated the effectiveness of the intervention across two VA sites to include a more heterogeneous sample, and examined if lengthening the duration of the intervention period to 6 months would translate into improvements in exercise capacity. At 6 months, participants who were assigned to the web-based intervention walked on average 1312 more steps per day compared to those who were assigned to usual care.\textsuperscript{58} Across these three studies, despite the significant improvements in daily step count (779–1312), there were no significant differences between the intervention and control groups in changes with respect to exercise capacity (6MWT distance) or dyspnea (mMRC).\textsuperscript{56–58}

Additionally, a priority in PR is to facilitate behavior change so patients will sustain engagement in long-term exercise. However, it remains difficult to maintain improvements in exercise after PR. Coutsal et al tested the efficacy of a 20-week, telephone-based lifestyle PA intervention compared to usual care in COPD patients eligible for PR. They did not find significant differences for their primary outcome of 6MWT distance; however, subgroup analysis found that among Veterans with moderate COPD, the intervention resulted in stability of 6MWT distance at 18 months compared to participants who received usual care.\textsuperscript{60} In addition to daily walking, the effectiveness of alternative exercise forms, such as Tai Chi and yoga, has been explored in Veterans with COPD. Tai Chi may be a promising intervention to support physical outcomes. Compared to a mind-body breathing intervention, a Tai Chi intervention resulted in more substantial improvements in exercise capacity (6MWT distance) among persons with COPD.\textsuperscript{61} Similarly, a recent pilot RCT found that Tai Chi after completion of PR may support maintaining exercise capacity (6MWT distance) compared to usual care in persons with COPD after completing PR.\textsuperscript{62} Results from another RCT suggest that Tai Chi over 6 months may help to maintain exercise capacity.\textsuperscript{63} However, participants in the RCT reported barriers to attending the Tai Chi program similar to those reported for center-based PR (ie, distance, time).\textsuperscript{63} One recent pilot examined the effect of yoga training on inspiratory muscle performance.\textsuperscript{64} Inspiratory muscle strength is impaired in patients with COPD and leads to debilitating dyspnea and poor functional performance.\textsuperscript{65} Veterans were assigned to a 6-
week yoga training program that included poses (asana) and controlled breathing (pranayama). Inspiratory muscle performance (measured via the Test of Incremental Respiratory Endurance) significantly improved from baseline, although no significant improvements were seen in exercise capacity (6MWT distance). In many patients with COPD, dynamic hyperinflation of the lungs during exercise is a major contributor to decreased exercise capacity. A recent study in Veterans examined if breathing retraining coupled with exercise training, a cornerstone of PR, would improve exercise capacity more than exercise training alone. Exercise training occurred via treadmill and took place three times every week for 12 weeks. The researchers used a metronome to provide acoustic feedback to train participants to achieve a slower respiratory rate and prolonged exhalation. Overall, despite achieving changes in breathing pattern with breathing retraining, improvements in exercise duration and dynamic hyperinflation were not significantly different with exercise training plus breathing retraining versus with exercise training alone.

**Psychological Outcomes and Interventions to Optimize Them in Veterans with COPD**

Depressive disorders are by far the most studied psychological disorder among Veterans with COPD. Rates of depressive disorder diagnosed by structured clinical interview range from 38% to 86% based on the study sample. Rates of diagnosed anxiety disorders range from 23% to 61%. Despite the high prevalence of depression and anxiety in Veterans with COPD, only a third receive any mental health treatment. In cross-sectional studies of Veterans, clinically significant depression symptoms were associated with low PA levels, worse self-reported functional impairment, greater dyspnea, and worse HRQoL. Moreover, epidemiological studies in large samples of Veterans with COPD have shown that depression is associated with 1.53 times higher 30-day mortality compared to Veterans without depression. Depression was also associated with 1.36 times increased risk of 30-day hospital readmission for COPD acute exacerbation. Clinically significant anxiety among Veterans with COPD shows similar associations to health and functional outcomes such as depression. Anxiety symptoms are associated with greater self-reported functional impairment and worse HRQoL. One study found a significant association between clinically significant anxiety and greater daily PA, a finding that requires replication in prospective studies. Anxiety is associated with 1.72 times higher 30-day mortality compared to Veterans without anxiety and 1.22 times increased risk of 30-day hospital readmission for COPD acute exacerbation.

Insomnia is an independent psychological disorder characterized by difficulty initiating or maintaining sleep, or early morning awakenings that cause significant distress and occur outside the diagnosis of another mental health condition. Research on insomnia in Veterans remains scarce. In one study, insomnia was found to occur in 27% (50 of 183) of Veterans with COPD. A much larger percentage of Veterans reported sleep complaints with 50% of the sample reporting at least one or more sleep complaint more than three times per week.

A key outcome in Veterans with COPD, HRQoL, reflects an individual’s perception of their quality of life when they consider their overall health (eg, 36-Item Short Form Survey (SF-36)) or in reference to their COPD diagnosis (eg, The Chronic Respiratory Questionnaire). Illness intrusiveness, a psychological construct, describes the extent to which an individual perceives their illness to impede in their daily life and valued activities and can be assessed with self-report measures. It is a meaningful treatment outcome for Veterans with COPD who prioritize daily functioning. The VHA has prioritized intervention development to improve psychological outcomes in Veterans with COPD. The following sections describe several of these interventions and their impact on psychological outcomes.

**Cognitive Behavioral Therapy (CBT)**

CBT is a time-limited, collaborative, present-focused, skills-based intervention that focuses on behavioral and cognitive change to treat psychological disorders. CBT is transdiagnostic, thus applicable in the treatment of the most common psychological disorders in COPD. Fundamental to CBT is that suffering is not directly caused by events themselves, but is a result of clients’ interpretation, appraisal, meaning, and behavioral response attached to events. Thus, treatment focuses on addressing the connection between events, thoughts, emotions, and behaviors while challenging and modifying unhelpful patterns.
While CBT has been studied by several research groups in civilian samples with COPD, only one research group in the US accounts for almost all empirical research on the efficacy of CBT in Veterans with COPD. Cully et al\textsuperscript{81} conducted an RCT comparing brief cognitive behavioral therapy (bCBT) to enhanced usual care (EUC) in 302 Veterans with either heart failure (HF) or COPD and clinically significant depression and/or anxiety symptoms. The primary outcomes were depression and anxiety symptoms measured by validated self-report measures. HRQoL was the secondary outcome.

bCBT was delivered in six sessions either in-person or by telephone based on patient preference with two booster sessions provided over four months. Each session focused on a particular skill and the number of sessions varied based on patient preference and discussion with their therapist. Skill sessions focused on modification of unhelpful thinking patterns, behavioral activation, relaxation, and chronic disease self-management. Content was adapted to focus on the intersection between physical symptoms and mental health. Like traditional CBT, bCBT addressed topics such as usual and past coping styles and strengths and resources in the patient’s life. Skills were taught alongside practice assignments focused on goal setting and modifying behavior and thinking patterns. Therapists for the study ranged from psychology and social work trainees to staff psychologists and physician assistants. The EUC group received assessment of mental health symptoms and a note in their chart for their primary care provider to address these concerns. Outcomes were assessed at baseline and 4 (post-intervention), 8, and 12 months.

At 4 months, there were meaningful improvements in depression and anxiety symptoms in patients with COPD or HF. Veterans with COPD showed significant improvement in all domains of HRQoL. At 12 months, differences were maintained between the treatment and control group, but there was no further improvement in symptoms.\textsuperscript{81}

Stemming from this parent study, secondary analyses were conducted in several separate articles and provide important insights into the optimization of psychological health in Veterans with COPD. First, the impact of bCBT on illness intrusiveness was examined among Veterans with COPD in the parent study.\textsuperscript{82} Illness intrusiveness was measured with the Illness Intrusiveness Rating Scale (IIRS) which provides a total score, as well as three validated subscales: Relationships (eg, family, civil engagement), Intimacy (eg, sexual functioning, relationship with spouse), and Instrumental (eg, health, work, active recreation). bCBT significantly improved IIRS total score at four months compared to EUC. At the subscale level, differences were found for Intimacy and Instrumental but not Relationships.

Second, in a separate study,\textsuperscript{83} bCBT was found to result in a significant reduction of high-frequency suicidal ideation (SI) in the bCBT group compared to the EUC at 4- and 8-month time points after controlling for baseline SI but the treatment effect was not sustained at 12 months. Specifically, at 4 and 8 months, respectively, participants who received bCBT compared to EUC had 72\% and 68\% lower likelihood of reporting high-frequency SI.

Third, predictors of treatment response to bCBT were explored in secondary analysis. Multivariate regression models examined whether hypothesized baseline variables including baseline depression or anxiety symptoms, functional limitations, self-efficacy for disease management, adaptive coping, maladaptive coping, number of sessions attended, and working alliance (ie, relationship between therapist and client) predicted improvement in primary outcomes of depression symptoms or anxiety symptoms. The same predictors emerged for both improvement in depression and anxiety symptoms. Participants with greater physical functioning impairment and lower self-efficacy showed less improvement in anxiety and depression symptoms. Those with greater baseline depression or anxiety showed greater improvement in symptoms.

The fourth and final study stemming from the parent study describes a utilization analysis of the content delivered in bCBT.\textsuperscript{85} They found that participants who received the “physical health” and “thoughts” modules earlier in treatment had a greater likelihood of remaining in treatment. Results have important clinical implications suggesting that early psychoeducation and skill building should focus on the intersection between physical and mental health, as well as dysfunctional or unhelpful thought patterns to optimize treatment completion rates. Together, these studies offer important data on the efficacy of bCBT, as well as treatment predictors.

\textbf{Pulmonary Rehabilitation and Physical Activity}

As described in the physical outcomes section, PR is the standard of care for Veterans with COPD targeting exercise capacity and physical functioning. However, PR also improves many psychological outcomes, but studies with Veteran samples are limited. In a retrospective study, Veterans with COPD who participated in twice weekly outpatient PR for 18
weeks demonstrated significant improvement in depression symptoms over the course of PR. Greater reduction in depression over the course of treatment was significantly associated with greater improvement in CRQ-SR total score and the following subscales: fatigue, mastery, and emotional function. 86 Similar findings were documented in a prior study examining the relation between change in depression symptoms and change in CRQ-SR subscales. In a sample of 81 Veterans enrolled in 8 weeks of biweekly PR, significant improvements were found for depression symptoms but not anxiety symptoms. Moreover, change in depression symptoms, but not anxiety symptoms, was associated with change in CRQ-SR domains of fatigue, emotion, and mastery. 87 PR, a core treatment for Veterans with COPD and significant depression symptoms, improves physical functioning and psychological outcomes. However, depression and anxiety symptoms, particularly in Veterans with more than one mental health diagnosis and/or lifetime/chronic course of psychological disorders may require more intensive outpatient therapy specifically for mental health following PR or concurrently. Re-assessment of depression and anxiety symptoms is important at the end of PR to determine treatment needs.

Other work within VA has examined the effect of PR on insomnia. A recent retrospective study examined subjective and objective sleep changes after eight weeks of conventional, in-person, structured PR and 12 months of an unstructured exercise program. 88 Despite sustained improvements in exercise capacity (measured via the 6MWT distance; mean improvement 68.8 m) and dyspnea (measured via the mMRC; mean difference −0.4 points), neither subjective sleep (measured via the Pittsburgh Sleep Quality Index) nor objective sleep (measured via actigraphy) improved. 88

Surprisingly, research testing PA interventions in Veterans with COPD has not found significant improvements in depression or anxiety symptoms. One VA-based study compared the effects of a 4-month pedometer plus internet-mediated intervention to waitlist control (pedometer) on HRQoL in Veterans with COPD measured at 4 and 12 months. 56,89,90 While HRQoL improved in the intervention group compared to the control group at 4 months, there was no difference at 12 months. Moreover, no change in depression scores was observed at either 4 or 12 months. However, these results are confounded by the fact that the treatment of anxiety and depression was not the main focus nor well characterized in the sample. For example, participants were not recruited based on significant levels of depression and anxiety nor was the intervention personalized in any way to participants based on their depression and/or anxiety levels.

Pharmacotherapy
Research on pharmacotherapy to improve psychological outcomes in individuals with COPD is limited in both civilian and Veterans samples. Drawing from the general literature, a Cochrane review published in 2018 found insufficient evidence for pharmacotherapy for the treatment of depression in individuals with COPD. 91 In their review of the literature on anti-depressants for depression in COPD, no recommendation was made for any anti-depressant type. Rather, non-pharmacological treatments, such as collaborative care models and CBT, were encouraged as first-line therapy. 92

Future Directions to Advance COPD Research and Clinical Care in Veterans with COPD
Advances in Physiological Outcomes
Pharmacological treatment of COPD is focused on maximizing lung function, reducing risk for acute exacerbations, and symptoms management, namely the reduction of dyspnea. 93 More recently, advances in COPD treatment have utilized precision medicine to target COPD in its early stages or before disease onset. 94 However, to our knowledge, there are few funded research studies in the VHA focused on early COPD or prevention efforts. This is notable given that Veterans of the Iraq and Afghanistan conflicts will be entering midlife and have already been identified to be at greater risk for respiratory diseases given environmental exposures. 95 Prior studies in civilians have begun to characterize those who may have “early” COPD targeting adults <50 years of age with ≥10 pack-years of smoking history with evidence of lung function abnormality by CT or spirometry that do not meet criteria for COPD. 96 Improved understanding of Preserved Ratio Impaired Spirometry, a classification of individuals who have proportional reductions in FEV₁ and FVC but preserved ratio, provides a group of individuals at higher risk for transitioning to COPD and may particularly benefit from early intervention. 97 Advances in imaging technology can help identify those who may be at-risk for COPD. 98 At
least one funded study within the VHA is exploring the application of computation imaging technology (CT) using Quantitative Imaging Analysis (QIA) to identify structural defects in the lungs before disease onset. By targeting individuals in the early COPD stage, effective clinical management can be offered and presents a vital area for future research in Veterans.

Similarly, identification of predictive biomarkers within COPD remains an active area of research with many unanswered questions. While review of the research on biomarkers of COPD is beyond the scope of this paper, more research is needed exploring COPD biomarkers in Veterans with careful delineation of endotypes connected to the proposed biomarker and clinical manifestation of disease activity. For example, past research in civilians established an association between epigenetic changes and inflammatory-response cytokines in COPD patients undergoing a prolonged, 24-session exercise training regimen. Early changes were observed in DNA methylation between baseline and after the first session but no changes were observed in H4 acetylation status at any point during the intervention. Inflammatory markers changed in response to the exercise intervention with an increase in interleukin-6 (IL-6) and a decrease in growth factor-beta after session 24.

In Veteran samples using a cross-sectional design, greater daily step count and higher 6MWT distance were associated with lower systematic inflammation, as measured by CRP and IL-6. After controlling for age, FEV1%, predicted, pack-years smoked, cardiac disease, current statin use, history of acute exacerbations, and season, each 1000-step increase in daily step count was significantly associated with 0.94 mg/L and 0.96 pg/mL decrease in CRP level. Similarly, for every 30-m increase in 6MWT distance, there was a 0.94 pg/mL decrease in CRP and 0.96 pg/mL decrease in IL-6 level. While not causal, these studies point to potential epigenetic changes associated with exercise-induced inflammatory biomarkers in COPD.

Research with Veteran samples has established correlations between epigenetic markers of biological age and functioning in COPD. At baseline, epigenetic age and age acceleration, measures that capture the difference between biological and chronological age, were inversely associated with 6MWT distance and PA after adjusting for chronological age, sex, race, smoking status, pack-years, BMI, cohort, and estimated cell counts. Importantly, longitudinal change in one of the measures of epigenetic age was inversely associated with change in 6MWT distance at 12 weeks, suggesting that epigenetic age may represent a potentially modifiable molecular signature of exercise capacity. Potential applications of epigenetics and biomarkers for the prediction of clinical outcomes, such as COPD acute exacerbations or response to exercise training programs such as pulmonary rehabilitation, represent active areas of investigation.

Advances in Physical Functioning

While PA promotion interventions show promising short- and some long-term benefit in terms of increasing daily PA and reducing COPD acute exacerbation risk, improvements in exercise capacity have not been observed. In the next decade, RCTs are needed to test the dose of PA promotion (ie, duration, intensity) required to sustain functional improvements. Long-term trials testing beyond 12 months are necessary. Moreover, development and testing of novel interventions that leverage varying levels of Veteran engagement, such as hybrid approaches that combine self-guided and in-person/ provider-delivered components are needed to examine the impact of frequency of promotional and supportive messages and check-ins from staff. Additionally, little is known about the social context and its association with short- and long-term adoption of PA. Studies exploring the role caregivers, family members, and friends in the adoption and maintenance of PA in COPD are needed, particularly given that social context has proved important for the success of COPD self-management efforts.

Finally, it is important to consider the effects of the COVID-19 pandemic on habitual PA and exercise patterns. Indoor walking and exercise in malls, gyms, and senior centers have been reduced and alternatives are not always available. As such, innovative research is needed to better understand how patients with COPD prefer to engage in PA in their current environments and preferences for in-home exercises.

Notably, the VHA is a leader in telemedicine and prioritized access to care well before the COVID-19 pandemic which only expanded over the last two years. The VHA system provides iPad, with built in internet access, at no cost to Veterans without a personal device and/or internet access. Moreover, the VA has an established Care Coordination/ Home Telehealth (CCHT) for chronic diseases including COPD, which provides home equipment for daily monitoring.
and disease management by a nurse care coordinator. In 2017, from funding through the VA’s Office of Rural Health, home-based PR was offered across 13 VA medical centers. While several studies in civilians have established the efficacy of home-based PR, until 2017 only hospital-based PR was offered in the VHA system. Based on home-based cardiac rehabilitation provided in the VA, home-based PR involves an initial in-person evaluation, followed by 11 weekly telephone or video appointments, an in-person evaluation at week 12, and follow-up phone/video calls at 3 and 6 months. A final in-person evaluation occurs at 12 months from the start of the program. However, the extent to virtual only rehabilitation and exercise programs are available to Veterans varies by VA. Future research is needed to demonstrate implementation of existing evidence-based PR programs delivered virtually in the VHA as part of routine clinical care.

Advances in Psychological Functioning
There is extensive evidence documenting increased inflammatory markers in psychological disorders and, in particular, major depressive disorder. Increases in pro-inflammatory markers including peripheral blood IL-1β, IL-6, Tumor Necrosis Factor (TNF) and C-reactive protein (CRP) are well documented. Yet, the role of inflammation and shared pathways between depression and COPD remain inconclusive. Limited cross-sectional research on civilians with COPD has found that greater depression symptoms are associated with higher TNF-α and sTNFR after adjusting for possible confounders. However, one prospective study did not find a significant association between depression and inflammatory markers in individuals with stable COPD. Janssen et al measured several inflammatory markers (white blood cell, hsCRP, IL6, fibrinogen) in COPD patients at baseline and 36-month follow-up. They classified individuals as having persistent systemic inflammation if they had 2 or more markers elevated in the upper quartile at baseline and follow-up or no inflammation corresponding to no elevation in inflammation at either time point. They found no association between baseline depression scores and inflammation group after adjusting for confounders, and no differences were found either in change in depression scores or mean levels at follow-up between inflammation groups. Nonetheless, given the notable role of inflammation in both COPD and depression, as well as the heterogeneity of both diseases, future research examining the association between inflammation and depression in COPD utilizing prospective designs is needed. Furthermore, reduction in inflammatory markers reflects a meaningful marker of treatment response in COPD and depression, thus it is plausible that targeting both COPD symptoms and depression concurrently could result in greater reduction in inflammatory markers corresponding to treatment response compared standalone therapies that separately target physical functioning and psychological symptoms.

In order to advance interventions for psychological outcomes in COPD, it is critical that researchers begin dually targeting both physical functioning and psychological outcomes. For example, past research with patients with diabetes and HF found that combining a physical intervention (ie, exercise) with psychotherapy (ie, CBT) produced superior outcomes in both functioning and mental health symptoms. Yet, up to this point, two independent bodies of literature have focused on separately addressing physical functioning via pulmonary rehabilitation and exercise, and mental health through psychotherapy/behavioral interventions. One funded study in the VHA is testing the integration of a pedometer-based walking intervention with CBT in a 12-week virtual intervention with Veterans with COPD, low PA levels, and clinically significant depression and/or anxiety symptoms (NCT04953806). The intervention will target daily step count and self-reported physical disability, as well as depression and anxiety symptoms.

Future Areas for Clinical Improvement
While research establishing the efficacy of treatments for COPD has been fruitful, implementation of guideline-based care remains fraught with health-care inequities. Women Veterans hospitalized for COPD are less likely to have received inhaler therapies prior to admission compared to men. In addition, women are less likely during the course of a COPD hospitalization to receive appropriate inhaler combinations and more likely to receive inappropriate inhaler combinations. Moreover, women, racial and ethnic minorities, and individuals with drug and alcohol use disorders are less likely to have pulmonary function tests performed, possibly leading to delays in diagnosis and under-treatment. In considering optimizing outcomes, it is imperative to consider and equally target health-care inequities that serve as barriers to guideline-based care. Similarly, enhanced recruitment of underserved groups (ie, lower socioeconomic status, racial and ethnic minorities) in COPD research...
studies is needed. Research and quality improvement projects are important to examine system and individual-level approaches to ensure equity in guideline-based care for all Veterans with COPD. Funding for COPD research that include focus on minority healthcare is needed.

Conclusions
The coming decade will see an increase in COPD prevalence in US Veterans as Vietnam era Veterans fully reach older adulthood and Iraq and Afghanistan conflict Veterans enter midlife. A multi-pronged agenda targeting system-level factors that increase access and improve care delivery, as well as bench and clinical research will be needed to advance our understanding, treatment, and management of COPD in Veterans. Partnerships with all stakeholders including patients, university-affiliated hospitals, industry, and the international research community will be critical to accelerate the development and implementation of novel treatments to improve physiological, physical, and psychological health outcomes for this heterogenous disease.

Funding
This work was supported, in part, by the following grants from the US Department of Veterans Affairs Rehabilitation Research and Development Service: Merit Award I01 RX001150 (M.L.M.); Career Development Award-2 (CDA2) Award I1K2RX003527-01A2 (P.M.B.); and CDA2 Award IK2RX002165 (E.S.W.).

Disclosure
The authors report no conflicts of interest in this work.

References
1. National Center for Veterans Analysis and Statistics. VA utilization profile FY2017. Available from: https://www.va.gov/vetdata/docs/QuickfactsVA_Utilization_Profile_2017.pdf. Accessed May 20, 2022.
2. Wang ZJ, Dhanireddy P, Prince C, Larsen M, Schimpf M, Pearson G. 2019 survey of veteran enrollees’ health and use of health care. Available from: https://www.va.gov/HEALTHPOLICYPLANNING/SOE2019/2019_Enrollee_Data_Findings_Report-March_2020_508_Compliant.pdf. Accessed May 20, 2022.
3. Percentage distribution of household income in the US in 2020. Available from: https://www.statista.com/statistics/203183/percentage-distribution-of-household-income-in-the-us/. Accessed May 20, 2022.
4. Jamal A, Phillips E, Gentzke AS, et al. Current cigarette smoking among adults - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(2):53–59. doi:10.15585/mmwr.mm6702a1
5. Pugh MJ, Jaramillo CA, Leung KW, et al. Increasing prevalence of chronic lung disease in veterans of the wars in Iraq and Afghanistan. Mil Med. 2016;181(5):476–481. doi:10.7205/MILMED-D-15-00035
6. Sharañkhané A, Petersen NJ, Yu H, Dalal AA, Johnson ML, Hanania NA. Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population. Int J Chron Obstruct Pulmon Dis. 2010;5:125–132. doi:10.2147/copd.s8047
7. Group TMoCOPDW. VA/DOD clinical practice guidelines for the management of chronic obstructive pulmonary disease. 2021.
8. Darnell K, Dwivedi AK, Weng Z, Panos RJ. Disproportionate utilization of healthcare resources among veterans with COPD: a retrospective analysis of factors associated with COPD healthcare cost. Cost Eff Resour Alloc. 2013;11:13. doi:10.1186/1478-7547-11-13
9. Wheaton AG, Liu Y, Croft JB, et al. Chronic obstructive pulmonary disease and smoking status - United States, 2017. MMWR Morb Mortal Wkly Rep. 2019;68(24):533–538. doi:10.15585/mmwr.mm6824a1
10. Murphy DE, Chaudhry Z, Almoosa KF, Panos RJ. High prevalence of chronic obstructive pulmonary disease among veterans in the urban midwest. Mil Med. 2011;176(5):552–560. doi:10.7205/MILMED-D-10-00377
11. Karel MJ, Wray LO, Adler G, et al. Mental health needs of aging veterans: recent evidence and clinical recommendations. Clin Gerontol. 2022;45(2):252–271. doi:10.1080/07317115.2020.1716910
12. Schüz N, Walters JA, Cameron-Tucker H, Scott J, Wood-Baker R, Walters EH. Patient anxiety and depression moderate the effects of increased self-management knowledge on physical activity: a secondary analysis of a randomised controlled trial on health-mentoring in COPD. COPD. 2015;12(5):502–509. doi:10.3109/15412555.2014.995289
13. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2022 report; 2021. Available from: https://goldcopd.org/2022-gold-reports-2/. Accessed December 20, 2021.
14. Bosse R, Sparrow D, Rose CL, Weiss ST. Longitudinal effect of age and smoking cessation on pulmonary function. Am Rev Respir Dis. 1981;123(4 Pt 1):378–381. doi:10.1164/ard.1981.123.4.378
15. Bremen M, Nwanaji-Enwerem JC, Karrasch S, et al. Accelerated epigenetic aging as a risk factor for chronic obstructive pulmonary disease and decreased lung function in two prospective cohort studies. Aging. 2020;12(16):16539–16554. doi:10.18632/aging.103784
16. Bell B, Rose CL, Damon A. The Veterans Administration longitudinal study of healthy aging. Gerontologist. 1966;6(4):179–184. doi:10.1093/geront/6.4.179
17. Bosse R, Costa P, Cohen M, Podolsky S. Age, smoking inhalation, and pulmonary function. Arch Environ Health. 1975;30(10):495–498. doi:10.1080/00039896.1975.10666670

18. Mordukhovich I, Lepeule J, Couill BA, Sparrow D, Vokonas P, Schwartz J. The effect of oxidative stress polymorphisms on the association between long-term black carbon exposure and lung function among elderly men. Thorax. 2015;70(2):133–137. doi:10.1136/thoraxjnl-2014-206179

19. Humminghake GM, Cho MH, Tesaftziy Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med. 2009;361(27):2599–2608. doi:10.1056/NEJMoa0904006

20. Renzetti AD, McClement JH, Litt BD. The Veterans Administration cooperative study of pulmonary function. 3. Mortality in relation to respiratory function in chronic obstructive pulmonary disease. Aspen Emphysema Conf. 1968;9:367–378.

21. Dean NC, Brown JK, Himelman RB, Doherty JJ, Gold WM, Stulberg MS. Oxygen may improve dyspnea and endurance in patients with chronic obstructive pulmonary disease and only mild hypoxemia. Am Rev Respir Dis. 1992;146(4):941–945. doi:10.1164/ajrccm/146.4.941

22. Stewart BN, Hood CI, Block AJ. Long-term results of continuous oxygen therapy at sea level. Chest. 1975;68(4):486–492. doi:10.1378/chest.68.4.486

23. Long-Term Oxygen Treatment Trial Research Group. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med. 2016;375(17):1617–1627. doi:10.1056/NEJMoa1604344

24. GROUP* NOTT. Continuous or nocturnal oxygen therapy in hypoxic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93(3):391–398. doi:10.7326/0003-4819-93-3-391

25. Party MR. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981;1(8222):681–686.

26. Chetty KG, Despars JA, Giron A, Light RW. Conversion of COPD patients from multiple to single dose theophylline. Serum levels and symptom comparison. Chest. 1991;100(4):1064–1067. doi:10.1378/chest.100.4.1064

27. Berger R, Smith D. Effect of inhaled metaproterenol on exercise performance in patients with stable “fixed” airway obstruction. Am Rev Respir Dis. 1985;138(3):624–629. doi:10.1164/ajrccm/138.3.624

28. Stueve D, Doherty JJ, Despars JA, Ruz WS, Roos JC. Objective and subjective tremor responses to oral beta 2 agents on first exposure. A comparison of metaproterenol and terbutaline. Am Rev Respir Dis. 1982;126(4):607–610. doi:10.1164/arrd.1982.126.4.607

29. Beauford W, Saylor TT, Stansbury DW, Avalos K, Light RW. Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest. 1993;104(1):175–178. doi:10.1378/chest.104.1.175

30. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340(25):1941–1947. doi:10.1056/NEJM199906243402502

31. Albert RK, Connell J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi:10.1056/NEJMoa1106232

32. Lam J, Tonnu-Mihara I, Kenyon NJ, Kuhn BT. Comparative effectiveness of roflumilast and azithromycin for the treatment of chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2021;8(4):450–463. doi:10.15326/copd.2021.0224

33. Yeh SS, Phamunas D, Hafner A, Schuster MW. Risk factors for osteoporosis in a subgroup of elderly men in a Veterans Administration nursing home. J Invest Med. 2002;50(5):452–457. doi:10.1136/jim-50-05-06-05

34. Morden NE, Sullivan SD, Bartle B, Lee TA. Skeletal health in men with chronic lung disease: rates of testing, treatment, and fractures. Osteoporos Int. 2011;22(6):1855–1862. doi:10.1007/s00198-010-1423-y

35. Cote CG, Pinto-Plata VM, Marin JM, Nekach H, Dordelly LJ, Celli BR. The modified BODE index: validation with mortality in COPD. Eur Respir J. 2008;32(5):1269–1274. doi:10.1183/09031936.00138507

36. Dunson P, Mador MJ. The influence of body composition on pulmonary rehabilitation outcomes in chronic obstructive pulmonary disease patients. Lung. 2017;195(6):729–738. doi:10.1007/s00408-017-0505-y

37. Nunez ER, Johnson SW, Qian SX, et al. Patterns of pulmonary consultation for veterans with incident chronic obstructive pulmonary disease. Am Am Thorac Soc. 2021;18(7):1249–1250. doi:10.1513/AnnalsATS.202008-1075RL

38. Fan VS, Gaziano JM, Lew R, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med. 2012;156(10):673–683. doi:10.7326/0003-4819-156-10-201205150-00003

39. Ahumatar H, Naqibuddin M, Chung S, et al. Effect of a hospital-initiated program combining transitional care and long-term self-management support on outcomes of patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. JAMA. 2019;322(14):1371–1380. doi:10.1001/jama.2019.11982

40. Ashton CM, Souchek J, Petersen NJ, et al. Hospital use and survival among Veterans Affairs beneficiaries. N Engl J Med. 2003;349(17):1637–1646. doi:10.1056/NEJMsa032999

41. Reese RL, Clement SA, Syeda S, et al. Coordinated-transitional care for veterans with heart failure and chronic lung disease. J Am Geriatr Soc. 2019;67(7):1502–1507. doi:10.1111/jgs.15978

42. Rinne ST, Elwy AR, Bastian LA, Wong ES, Wiener RS, Li C-F. Impact of multisystem health care on readmission and follow-up among veterans hospitalized for chronic obstructive pulmonary disease. Med Care. 2017;55:S20–S25. doi:10.1097/mlr.0000000000000708

43. LaBedz SL, Krishnan JA, Chung YC, et al. Multisystem care and primary care: a comparison of multisystem care and primary care in veterans with COPD. J Am Geriatr Soc. 2017;65(8):S304–S313. doi:10.1161/cjg.2017.003016

44. O’Donnell DL, Milne K, James MD, De Torres JP, Neder JA. Dyspnea in COPD: new mechanistic insights and management implications. Am J Respir Crit Care Med. 2020;192(1):41–60. doi:10.1164/rccm.201906-0610PL

45. Hajmanbari B, Garland SJ, Road JD, Reid WD. Pain and physical performance in people with COPD. Respir Med. 2013;107(11):1692–1699. doi:10.1016/j.rmed.2013.06.010

46. Wan E, Goldstein R, Kantorowski A, Moy M. Association between exercise capacity and physical activity with long-term all-cause and cause-specific mortality among US veterans with COPD. In: TP41. TP41? DIAGNOSIS and RISK ASSESSMENT in COPD. American Thoracic Society; 2021:A2284–A2284.

47. Spruit MA, Pitta F, McAuley E, ZuWalla R, Nici L. Pulmonary rehabilitation and physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(8):924–933. doi:10.1164/rcrm.201505-0929OC
49. Fan VS, Giardino ND, Blough DK, Kaplan RM, Ramsey SD; Nett Research Group. Costs of pulmonary rehabilitation and predictors of adherence in the National Emphysema Treatment Trial. *COPD*. 2008;5(2):105–116. doi:10.1080/15412550801941190

50. Bamonti PM, Boyle JT, Goodwin CL, et al. Predictors of outpatient pulmonary rehabilitation uptake, adherence, completion, and treatment response among male US veterans with chronic obstructive pulmonary disease. *Arch Phys Med Rehabil*. 2021. doi:10.1016/j.apmre.2021.10.021

51. Sahin H, Naz I. Why are COPD patients unable to complete the outpatient pulmonary rehabilitation program? *Chron Respir Dis*. 2018;15(4):411–418. doi:10.1177/1749773817767206

52. Major S, Moreno M, Shelton J, Panos RJ. Veterans with chronic obstructive pulmonary disease achieve clinically relevant improvements in respiratory health after pulmonary rehabilitation. *J Cardiopulm Rehabil Prev*. 2014;34(6):420–429. doi:10.1097/hcr.0000000000000709

53. Vorrink SN, Kort HS, Troosters T, Lammers J-WI. Level of daily physical activity in individuals with COPD compared with healthy controls. *Respir Res*. 2011;12(1):33. doi:10.1186/1465-9921-12-33

54. Gimeno-Santos E, Frei A, Steurer-Stey C, et al. Determinants and outcomes of physical activity in patients with COPD: a systematic review. *Thorax*. 2014;69(8):731–739. doi:10.1136/thoraxjnl-2013-204763

55. Watz H, Pitta F, Rochester CL, et al. An official European Respiratory Society statement on physical activity in COPD. *Eur Respir Soc*. 2014;44:1521–1537. doi:10.1183/09031936.00046814

56. Moy ML, Collins RJ, Martinez CH, et al. An internet-mediated pedometer-based program improves health-related quality-of-life domains and daily step counts in COPD. *Chest*. 2015;148(1):128–137. doi:10.1378/chest.14-1466

57. Fan ES, Kantorowski A, Homsy D, et al. Promoting physical activity in COPD: insights from a randomized trial of a web-based intervention and pedometer use. *Respir Med*. 2017;130:102–110. doi:10.1016/j.rmed.2017.07.057

58. Robinson SA, Cooper JA, Goldstein RL, et al. A randomised trial of a web-based physical activity self-management intervention in COPD. *ERJ Open Res*. 2021;7:00158-2021. doi:10.1183/23120541.00158-2021

59. Wang ES, Kantorowski A, Polak M, et al. Long-term effects of web-based pedometer-mediated intervention on COPD exacerbations. *Respir Med*. 2020;162:105878. doi:10.1016/j.rmed.2020.105878

60. Coultas DB, Jackson BE, Russo R, et al. Lifestyle physical activity intervention for patients with chronic obstructive pulmonary disease: A randomized controlled trial. *Ann Am Thorac Soc*. 2016;13(5):617–626. doi:10.1513/AnnalsATS.201508-508OC

61. Kraemer KM, Litrownik D, Moy ML, et al. Exploring Tai Chi exercise and mind-body breathing in patients with COPD in a randomized controlled feasibility trial. *COPD*. 2021;18:1–11.

62. Moy ML, Wayne PM, Litrownik D, et al. Long-term Exercise After Pulmonary Rehabilitation (LEAP): a pilot randomised controlled trial of Tai Chi in COPD. *ERJ Open Res*. 2021;7:00025-2021. doi:10.1183/23120541.00025-2021

63. Yeh GY, Litrownik D, Wayne PM, et al. BEAM study (Breathing, Education, Awareness, Movement): a randomised controlled feasibility trial. *Respir Med*. 2020;162:105878. doi:10.1016/j.rmed.2020.105878

64. DeLuca ND, Vajta Gomez JP, Vital I, Cahalin LP, Campos MA. The impact of yoga on inspiratory muscle performance in veterans with COPD: a pilot study. *Int J Yoga Therap*. 2020;31:Article_4.

65. Formiga MF, Vital I, Urdaneta G, Balestrini K, Cahalin LP, Campos MA. The BODE index and inspiratory muscle performance in COPD: clinical findings and implications. *SAGE Open Med*. 2018;6:2050312118819015. doi:10.1177/2050312118819015

66. O’Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. *COPD*. 2006;3(4):219–232. doi:10.1080/15412550609747748

67. Collins EG, Jelinek C, O’Connell S, Butler J, Reda D, Laghi F. The effect of breathing retraining using metronome-based acoustic feedback on exercise endurance in COPD: a randomized trial. *Lung*. 2019;197(2):181–188. doi:10.1007/s00408-019-00198-4

68. Thompson PD, Buchner D, Piha AL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. *Circulation*. 2003;107(24):3109–3116. doi:10.1161/01.cir.0000075572.40158.77

69. Kunik ME, Roundy K, Vaezy C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. *Chest*. 2005;127(4):1205–1211. doi:10.1378/chest.127.4.1205

70. Ratcliff CG, Barrera TL, Petersen NJ, et al. Recognition of anxiety, depression, and PTSD in patients with COPD and CHF: who gets missed? *Prim Care Companion CNS Disord*. 2010;12(4):26595.

71. Nguyen HQ, Fan VS, Herting J, et al. Patients with COPD with higher levels of anxiety are more physically active. *Chest*. 2013;144(1):145–151. doi:10.1378/chest.127.4.1205

72. Felker B, Bush KR, Harel O, Shofer JB, Shores MM, Au DH. Added burden of mental disorders on health status among patients with chronic obstructive pulmonary disease. *Prim Care Companion CNS Disord*. 2010;12(4):26595.

73. Felker B, Katon W, Hedrick SC, et al. The association between depressive symptoms and health status in patients with chronic pulmonary disease. *Gen Hosp Psychiatry*. 2001;23(2):56–61. doi:10.1016/S0163-8343(01)00127-X

74. Kim HFS, Kunik ME, Molinari VA, et al. Functional impairment in COPD patients: the impact of anxiety and depression. *Psychosomatics*. 2000;41(6):465–471. doi:10.1177/0033291800041006

75. Abrams TE, Vaughan-Sarrarzin M, Vander Weg MW. Acute exacerbations of chronic obstructive pulmonary disease and the effect of existing psychiatric comorbidity on subsequent mortality. *Psychosomatics*. 2011;52(5):441–449. doi:10.1016/j.psym.2011.03.005

76. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Arlington, VA: American Psychiatric Association; 2013.

77. Bendorai R, Parthasarathy S, Budhira J, Habib MP, Wendel C, Quan SF. Insomnia in patients with COPD. *Sleep*. 2012;35(3):369–375. doi:10.5665/sleep.1698

78. Brazier JE, Harper R, Jones N, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. *Br Med J*. 1992;305(6846):160–164. doi:10.1136/bmj.305.6846.160

79. Wijkstra P, TenVergert E, Van Altena R, et al. Reliability and validity of the chronic respiratory questionnaire (CRQ). *Thorax*. 1994;49(5):465–467. doi:10.1136/thx.49.5.465

80. Bamonti P, Jacobs ML. Cognitive late life behavioral therapy in. In: *Psychotherapy in Later Life*. Cambridge University Press; 2020:35.

81. Culty JA, Stanley MA, Petersen NJ, et al. Delivery of brief cognitive behavioral therapy for medically ill patients in primary care: a pragmatic randomized clinical trial. *J Gen Intern Med*. 2017;32(9):1014–1024. doi:10.1007/s11606-017-4101-3
82. Renn BN, Hundt NE, Sansgiry S, et al. Integrated brief cognitive behavioral therapy improves illness intrusiveness in veterans with chronic obstructive pulmonary disease. *Ann Behav Med.* 2018;52(8):686–696. doi:10.1093/abm/kax045
83. Ecker AH, Johnson AL, Sansgiry S, et al. Brief cognitive behavioral therapy reduces suicidal ideation in veterans with chronic illnesses. *Gen Hosp Psychiatry.* 2019;58:27–32. doi:10.1016/j.genhosppsych.2019.02.002
84. Hundt NE, Bensadon BA, Stanley MA, et al. Coping mediates the relationship between disease severity and illness intrusiveness among chronically ill patients. *J Health Psychol.* 2015;20(9):1186–1195. doi:10.1177/1359105315590845
85. Brandt CP, Deavers F, Hundt NE, Fletcher TL, Cully JA. The impact of integrating physical health into a brief CBT approach for medically ill veterans. *J Clin Psychol Med Settings.* 2020;27(2):285–294. doi:10.1007/s10803-019-09634-2
86. Bamonti PM, Wiener CH, Weiskittle RE, et al. The impact of depression and exercise self-efficacy on benefits of pulmonary rehabilitation in veterans with COPD. *Behav Med.* 2021;1–11. doi:10.1089/behm.2020.1983755
87. Pirraglia PA, Casserly B, Velasco R, Borgia ML, Nici L. Association of change in depression and anxiety symptoms with functional outcomes in pulmonary rehabilitation patients. *J Psychosom Res.* 2011;71(1):45–49. doi:10.1016/j.jpsychres.2011.01.002
88. Thapamagor SB, Ellstrom K, Anholm JD, Fargo RA, Dandamudi N. Impact of pulmonary rehabilitation in sleep in COPD patients measured by actigraphy. *PLoS One.* 2021;16(3):e0248466. doi:10.1371/journal.pone.0248466
89. Kantorowski A, Wan ES, Homsy D, Kadri R, Richardson CR, Moy ML. Determinants and outcomes of change in physical activity in COPD. *ERJ Open Res.* 2018;4(3). doi:10.1183/23120454.000548-2018
90. Moy ML, Martinez CH, Kadri R, et al. Long-term effects of an internet-mediated pedometer-based walking program for chronic obstructive pulmonary disease: randomized controlled trial. *J Med Internet Res.* 2016;18(8):e215. doi:10.2196/jmir.5622
91. Pollok J, van Agteren JE, Carson-Chahoud KV. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2018;18(12). doi:10.1002/14651858.CD012346.pub2
92. Yohannes A, Alexopoulos G. Pharmacological treatment of depression in older patients with chronic obstructive pulmonary disease: impact on the course of the disease and health outcomes. *Drugs Aging.* 2014;31(7):483–492. doi:10.1007/s40266-014-0186-9
93. Singh D. Pharmacological treatment of stable chronic obstructive pulmonary disease. *Respir Med.* 2021;6:464–651. doi:10.1111/resp.14046
94. Sidhaye VK, Nishida K, Martinez FJ. Precision medicine in COPD: where are we and where do we need to go? *Eur Respir Rev.* 2018;27:149. doi:10.1183/16990402.00069-2018
95. Smith B, Wong CA, Smith TC, Boyko EJ, Gackstatter GD, Team MARRMCS. Newly reported respiratory symptoms and conditions among military personnel deployed to Iraq and Afghanistan: a prospective population-based study. *Am J Epidemiol.* 2009;170(11):1433–1442. doi:10.1093/aje/kwp287
96. Martinez FJ, Han MK, Allinson JP, et al. At the root: defining and halting progression of early chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2018;197(19):1540–1551. doi:10.1164/rccm.201710-2088PP
97. Wan ES, Fortis S, Regan EA, et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study. *Am J Respir Crit Care Med.* 2018;198(11):1397–1405. doi:10.1164/rccm.201804-0663OC
98. Xia C, Rook M, Pelgrim GJ, et al. Early imaging biomarkers of lung cancer, COPD and coronary artery disease in the general population: rationale and design of the ImaLife (Imaging in Lifelines) study. *Eur J Epidemiol.* 2020;35(1):75–86. doi:10.1007/s10654-019-00519-0
99. Stockley RA, Halpin DM, Celli BR, Singh D. Chronic obstructive pulmonary disease biomarkers and their interpretation. *Am J Respir Crit Care Med.* 2019;199(10):1195–1204. doi:10.1164/rccm.201811-2165OSO
100. da Silva IRV, de Araujo CLP, Dorneles GP, et al. Exercise-modulated epigenetic markers and inflammatory response in COPD individuals: a pilot study. *Respir Physiol Neurobiol.* 2017;242:89–95. doi:10.1016/j.resp.2017.04.004
101. Moy ML, Teylan M, Weston NA, Gagnon DR, Danilack VA, Garshick E. Daily step count is associated with plasma C-reactive protein and IL-6 in a US cohort with COPD. *Chest.* 2014;145(3):542–550. doi:10.1378/chest.13-1052
102. Wan ES, Goldstein RL, Gasheicke E, DeMeo DL, Moy ML. Molecular markers of aging, exercise capacity, & physical activity in COPD. *Respir Med.* 2021;187:106576. doi:10.1164/rmed.2021.106576
103. Chen Z, Fan VS, Belza B, Pike K, Nguyen HQ. Association between social support and self-care behaviors in adults with chronic obstructive pulmonary disease. *Am Ann Thorac Soc.* 2017;14(9):1419–1427. doi:10.1513/AnnalsATS.201701-0260OC
104. Lenerrink A, van der Palen J, Effing T. The role of social support in improving chronic obstructive pulmonary disease self-management. *Expert Rev Respir Med.* 2018;12(8):623–626. doi:10.1080/19316914.2018.1489723
105. Vetrovsky T, Frybova T, Gant I, et al. The detrimental effect of COVID-19 nationwide quarantine on accelerometer-assessed physical activity of heart failure patients. *ESC Heart Failure.* 2020;7(5):2093–2097. doi:10.1002/ehf2.12916
106. Wang Y, Zhang Y, Bennell K, et al. Physical distancing measures and walking activity in middle-aged and older residents in Changsha, China, during the COVID-19 epidemic period: longitudinal observational study. *J Med Internet Res.* 2020;22(10):e21632. doi:10.2196/21632
107. Tuerk PW, Fortney J, Bosworth HB, et al. Toward the development of national telehealth services: the role of Veterans Health Administration and Future Directions for Research. *Telemed e-Health.* 2010;16(1):115–117. doi:10.1089/tmj.2009.0144
108. Connolly SL, Stolzmann KL, Heyworth L, Weaver KR, Bauer MS, Miller CJ. Rapid increase in telemental health within the Department of Veterans Affairs during the COVID-19 pandemic. *Telemed e-Health.* 2021;27(4):454–458. doi:10.1089/tmj.2020.0233
109. Singh D, Ryan P, Cobb R, et al. Care Coordination/Home Telehealth: the systematic implementation of health informatics, home telehealth, and disease management to support the care of veteran patients with chronic conditions. *Telemed e-Health.* 2008;14(10):1118–1126. doi:10.1089/tmj.2008.0021
110. Holland AE, Mahal A, Hill CJ, et al. Home-based rehabilitation for COPD using minimal resources: a randomised, controlled equivalence trial. *Thorax.* 2017;72(1):57–65. doi:10.1136/thoraxjnl-2016-208514
111. Grosbois JM, Giacquelle A, Langlois C, et al. Long-term evaluation of home-based pulmonary rehabilitation in patients with COPD. *Int J Chron Obstruct Pulmon Dis.* 2015;10:2037. doi:10.2147/COPD.S90534
112. Drwal KR, Wakefield BJ, Forman DE, Wu W-C, Haraldsson B, El Accaoui RN. Home-based cardiac rehabilitation: experience from the Veterans Affairs. *J Cardiopulm Rehabil Prev.* 2021;41(2):93–99. doi:10.1097/HCR.0000000000000594
113. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol.* 2016;16(1):22–34. doi:10.1038/nri.2015.5
114. Eagan T, Ueland T, Wagner P, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. *Eur Respir J*. 2010;35(3):540–548. doi:10.1183/09031936.00088209

115. Al-Shair K, Kolsum U, Dockry R, Morris J, Singh D, Vestbo J. Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. *Respir Res*. 2011;12(1):1–6. doi:10.1186/1465-9921-12-3

116. Janssen DJ, Müllerova H, Agusti A, et al. Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. *Respir Med*. 2014;108(11):1647–1654. doi:10.1016/j.rmed.2014.07.013

117. Moreira FP, de Azevedo Cardoso T, Mondin TC, et al. The effect of proinflammatory cytokines in Cognitive Behavioral Therapy. *J Neuroimmunol*. 2015;285:143–146. doi:10.1016/j.jneuroim.2015.06.004

118. Gary RA, Dunbar SB, Higgins MK, Musselman DL, Smith AL. Combined exercise and cognitive behavioral therapy improves outcomes in patients with heart failure. *J Psychosom Res*. 2010;69(2):119–131. doi:10.1016/j.jpsychiores.2010.01.013

119. Piette JD, Richardson C, Himle J, et al. A randomized trial of telephone counseling plus walking for depressed diabetes patients. *Med Care*. 2011;49(7):641. doi:10.1097/MLR.0b013e318215d0c9

120. Bade BC, DeRycke EC, Skanderson M, et al. Underutilization of pulmonary function testing in veterans hospitalized for chronic obstructive pulmonary disease exacerbation: who are we missing? *COPD*. 2020;17(1):15–21. doi:10.1080/15412555.2019.1711036